Showing results (1-10 of 628) with videos related to
Sort By:
Pageof 63
Hematology (Amsterdam, Netherlands)|February 12, 2013
Alloantibodies in previously untreated hemophilia A patients: the role of environmental factorsMassimo Franchini, Francesco Frattini, Silvia Crestani, et al.Seminars in Thrombosis and Hemostasis|December 19, 2012
Bleeding complications in patients with hematologic malignanciesMassimo Franchini, Francesco Frattini, Silvia Crestani, et al.Journal of Thrombosis and Thrombolysis|October 16, 2012
Acquired FXIII inhibitors: a systematic reviewMassimo Franchini, Francesco Frattini, Silvia Crestani, et al.Expert Opinion on Pharmacotherapy|September 6, 2012
Haemophilia B: current pharmacotherapy and future directionsMassimo Franchini, Francesco Frattini, Silvia Crestani, et al.Biologics : Targets & Therapy|February 23, 2013
Treatment of hemophilia B: focus on recombinant factor IXMassimo Franchini, Francesco Frattini, Silvia Crestani, et al.Seminars in Thrombosis and Hemostasis|June 18, 2014
Hemostatic agents for bleeding: recombinant-activated factor VII and beyondMassimo Franchini, Silvia Crestani, Francesco Frattini, et al.Clinical Chemistry and Laboratory Medicine|June 20, 2014
ABO blood group and von Willebrand factor: biological implicationsMassimo Franchini, Silvia Crestani, Francesco Frattini, et al.Journal of Thrombosis and Thrombolysis|July 13, 2014
Recombinant activated factor VII in clinical practice: a 2014 updateMassimo Franchini, Silvia Crestani, Francesco Frattini, et al.Thrombosis Research|February 12, 2013
von Willebrand factor and cancer: a renewed interestMassimo Franchini, Francesco Frattini, Silvia Crestani, et al.Seminars in Thrombosis and Hemostasis|June 29, 2012
Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literatureFrancesco Dentali, Anna Paola Sironi, Walter Ageno, et al.Pageof 63